| Knowledge-base field | MMDS2 summary | Evidence |
|---|---|---|
| Identity and identifiers | Multiple mitochondrial dysfunctions syndrome 2 (MMDS2); multiple mitochondrial dysfunctions syndrome type 2 with hyperglycinemia; BOLA3-related multiple mitochondrial dysfunction syndrome. **MONDO:** MONDO:0013675; **OMIM:** 614299. Specific ICD-10, ICD-11, MeSH, and Orphanet identifiers were not established from the retrieved evidence. | Open Targets independently maps MONDO:0013675 to BOLA3; systematic clinical literature identifies OMIM 614299 (pqac-00000000, pqac-00000003, pqac-00000004). |
| Gene and inheritance | Caused by **biallelic germline variants in BOLA3** (bolA family member 3; Ensembl ENSG00000163170). Inheritance is **autosomal recessive**; obligate heterozygous parents are generally unaffected. Penetrance has not been quantified but appears high for damaging biallelic genotypes. | Human genetic association and recessive pedigrees (pqac-00000000, pqac-00000003, pqac-00000005). |
| Reported population | A 2021 systematic review identified **18 patients from 14 families worldwide** and eight BOLA3 variants. Disease-specific prevalence, incidence, carrier frequency, sex ratio, and population-based survival statistics are unavailable. | Aggregated systematic-review evidence; very small, ascertainment-biased case series (pqac-00000006). |
| Onset and core neurologic phenotypes | Usually neonatal or infantile onset, commonly within the first year; prior cases in one comparison began from birth to 8 months. Motor delay or regression occurred in **12/12**, seizures in **5/10**, and independent walking in **1/5** evaluable previously reported patients. An attenuated case began acutely at 18 months with hemiparesis, ataxia, and speech/cognitive regression. | Patient-level and aggregated human evidence (pqac-00000002, pqac-00000003, pqac-00000005). |
| Multisystem manifestations | Severe cases may include hypotonia or weakness, feeding difficulty/failure to thrive, respiratory failure, optic atrophy or nystagmus, renal or hepatic failure, and cardiomyopathy. Cardiomyopathy occurred in **7/9** in one historical comparison and in approximately half of the 18-patient review cohort; hypertrophic and dilated forms were reported. | Aggregated human clinical evidence (pqac-00000002, pqac-00000004, pqac-00000006). |
| Biochemical markers | Typical abnormalities include elevated plasma/urine glycine, lactate, pyruvate, and metabolic acidosis; historical denominators were elevated lactate **11/12**, glycine **8/8**, reduced respiratory-chain complex I/II activity **10/12**, and reduced pyruvate-dehydrogenase activity **6/7**. Normal lactate or tissue respiratory-chain assays do not exclude MMDS2: the recovery case had elevated plasma/urine glycine, normal CSF glycine and lactate, but fibroblast PDH activity was **20% of control** with reduced complex I/II subunits. | Human biochemical evidence (pqac-00000002, pqac-00000005). |
| Neuroimaging | Characteristic MRI findings include bilateral diffuse or multifocal periventricular/deep-white-matter T2 hyperintensity, dysmyelination or cavitating/cystic leukodystrophy, restricted diffusion, corpus-callosum, brainstem, cerebellar, spinal-cord, or basal-ganglia involvement, and cerebral/cerebellar atrophy. MR spectroscopy may show a lactate peak and reduced N-acetylaspartate. | Human neuroradiologic evidence (pqac-00000002, pqac-00000005, pqac-00000007). |
| Key variants | Reported variants include **c.123dupA (p.Glu42Argfs*13), c.136C>T (p.Arg46*), c.159dupT (p.Asp54*), c.176G>A (p.Cys59Tyr), c.200T>A (p.Ile67Asn), c.220_222del (p.Glu74del), c.225_229del (p.Lys75Asnfs*9), c.287A>G (p.His96Arg), and c.295C>T (p.Arg99Trp)** across retrieved reports/reviews. The 2021 review counted eight variants; the larger list reflects subsequent/independently tabulated reports and should be reconciled against current ClinVar and transcript versions before database import. Population allele frequencies and current ACMG/ClinVar classifications were not retrieved. | Aggregated variant tables and case report (pqac-00000004, pqac-00000005, pqac-00000007). |
| Variant-specific functional effects | **p.Cys59Tyr:** retains partial Fe–S transfer; NFU1 became [4Fe–4S]-bound at **25% versus 65% with wild type**, consistent with an attenuated Arg46*/Cys59Tyr phenotype. **p.Ile67Asn:** preserves global fold but disrupts GLRX5 binding and BOLA3–GLRX5 heterocomplex formation. **p.His96Arg:** permits partner interaction but forms an aberrant complex unable to assemble an NFU1 [4Fe–4S] cluster. **p.Arg46\*:** predicted/truncating loss of function; direct functional quantification was not retrieved. | Recombinant-protein/in-vitro studies and human genotype–phenotype correlation; DOI 10.3390/ijms22094848, 10.1093/mtomcs/mfab010, and 10.3390/ijms241411734 (pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000012, pqac-00000015). |
| Core mechanism | BOLA3 and GLRX5 form a bridged [2Fe–2S] carrier complex that transfers clusters to NFU1, where reductive coupling generates [4Fe–4S] clusters. BOLA3 deficiency therefore impairs maturation of respiratory-chain Fe–S proteins and lipoic-acid synthase, reducing oxidative phosphorylation and lipoylation of PDH, α-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase, and glycine-cleavage proteins. The resulting ATP deficit, lactic acidosis, and impaired glycine cleavage lead to high-energy-tissue injury, particularly leukoencephalopathy and cardiomyopathy. | Biochemical and cellular evidence; some links from energy failure to tissue-selective clinical injury remain inferred (pqac-00000010, pqac-00000011, pqac-00000012). |
| 2023 mechanistic development | The **GLRX5–BOLA3 node also supplies [2Fe–2S] clusters to mitochondrial ribosomal subunits**. BOLA3 depletion reduced mitochondrial translation to **60–70% of control**, and five-day depletion made mitoribosomal ⁵⁵Fe incorporation virtually undetectable. BOLA3-mutant patient fibroblasts showed attenuated mitochondrial protein synthesis and defective assembled OXPHOS complexes, adding impaired mitoribosome assembly to the disease mechanism. | HEK293T knockdown and patient-fibroblast evidence; published online 12 October 2023, DOI 10.1093/nar/gkad842 (pqac-00000013, pqac-00000016). |
| Diagnosis | Suspect MMDS2 in early-onset regression, leukodystrophy, cardiomyopathy, lactic acidosis, and hyperglycinemia. Evaluate plasma/CSF/urine lactate, pyruvate and glycine; acylglycine/organic-acid profiles; brain MRI/MRS; ECG/echocardiography; ophthalmology; respiratory status; and respiratory-chain, PDH, and protein-lipoylation studies in fibroblasts or muscle where available. Confirm with a nuclear mitochondrial/leukodystrophy panel or WES/WGS identifying pathogenic biallelic BOLA3 variants, followed by segregation and, for uncertain variants, RNA or functional studies. This is an evidence-based diagnostic approach, not a formal disease-specific guideline. | Human diagnostic and review evidence (pqac-00000003, pqac-00000005, pqac-00000008). |
| Treatment and trials | No established disease-modifying therapy was identified. Management is supportive: nutrition and feeding support; treatment of seizures, acidosis, respiratory insufficiency, and heart failure; and physical, occupational, and speech rehabilitation. “Mitochondrial” vitamin/cofactor cocktails have been used without clear evidence of benefit; one possible partial methylprednisolone response is anecdotal and cannot establish efficacy. The retrieved ClinicalTrials.gov search found **no relevant MMDS2-specific interventional trial or NCT identifier**. | Case-based treatment evidence and direct trial-registry search (pqac-00000001, pqac-00000006). |
| Prognosis | Classical disease is severe, progressive, and frequently fatal in infancy or early childhood. In one historical series, survival ranged from **3 months to 11 years**, and recovery occurred in **0/10** evaluable prior cases. Genotype-dependent attenuation is documented: the Arg46*/Cys59Tyr patient recovered clinically over four years and was alive at age eight with improved MRI, while an Arg99Trp patient reportedly survived to age 12. Formal 5- or 10-year survival estimates are unavailable. | Human natural-history and genotype–phenotype evidence (pqac-00000002, pqac-00000003, pqac-00000006). |
| Evidence limitations | Evidence is dominated by individual patients, small retrospective case series, one systematic review, patient fibroblasts, gene-silencing models, and recombinant-protein experiments. Frequencies use incomplete and varying denominators; ascertainment favors severe cases. No population epidemiology, validated quality-of-life instruments, standardized diagnostic criteria, controlled treatment trials, prognostic model, protective variants, established modifier genes, disease-specific epigenomic signature, single-cell/spatial study, or validated biomarker was identified. | Cross-source evidence assessment (pqac-00000001, pqac-00000002, pqac-00000006, pqac-00000013). |


*Table: Concise disease-level summary of BOLA3-related MMDS2, integrating clinical frequencies, variants, mechanisms, diagnosis, management, prognosis, and major evidence gaps. Findings distinguish human observations from experimental or inferred mechanisms.*